insights_auto
Why is LCTX up 8,70%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
1,03 $
arrow_upward
+8,70%(+0,082) 1D
1,03 $
0,00% (0,00)
bedtimeAfter hours
Closed: 8 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
0,95 $
High
1,04 $
Low
0,93 $
Mkt. cap
259,91 млн
Avg. vol.
1,37 млн
Volume
2,01 млн
52-wk high
2,09 $
52-wk low
0,88 $
EPS
-0,14 $
Beta
1,60
Shares outstanding
252,91 млн
No. of employees
75
Open
0,95 $
High
1,04 $
Low
0,93 $
Mkt. cap
259,91 млн
Avg. vol.
1,37 млн
Volume
2,01 млн
52-wk high
2,09 $
52-wk low
0,88 $
EPS
-0,14 $
Beta
1,60
Shares outstanding
252,91 млн
No. of employees
75
News stories
From web sources and news partners
Renaissance Capital
·
1 сағат бұрын
Metal powder producer Amaero revives Nasdaq listing plans, slashing deal size by about 60% ahead of $20 million IPO
Simply Wall Street
·
41 минут бұрын
Does AST SpaceMobile (ASTS) Canada Test Change The Direct To Device Story?
Investor's Business Daily
·
1 сағат бұрын
Futures: AI Stocks Skid On OpenAI; SpaceX Move Hits Telecom Rivals
Yahoo Finance
·
1 сағат бұрын
XLG Cuts the S&P 500 Down to 50 Stocks. The Result Is an Index Fund Built Entirely Around Mega-Caps
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc